QXO Inc. Common Stock vs Teladoc Health Inc — how do they compare? QXO Inc. Common Stock trades at $10.36 (market cap $11.43B), while Teladoc Health Inc trades at $5.79 (market cap $1.09B). The key difference: QXO Inc. Common Stock is far larger — about 10.5× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, QXO Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold QXO Inc. Common Stock for 0 Days and Teladoc Health Inc for 39 Days on average.
| QXO | TDOC | |
|---|---|---|
Market Cap | $11.43B | $1.09B |
Volume | 21,645,941 | 4,279,268 |
Sector | Industrials | Health |
52-Week High | $27.07 | $9.72 |
52-Week Low | $10.33 | $4.47 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $16.75B | $1.35B |
Signals from Pluang's Aura AI — not financial advice
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
Teladoc Health (TDOC) trades at $5.81, down 1.86% on the day, with a bearish technical signal and mixed quarterly earnings performance. The company maintains strong gross margins at 68.97% but continues to report net losses, with a -7.13% net income margin for 2025. Recent developments include new executive appointments and ongoing legal investigations, while analyst consensus shows 35.71% buy ratings with a $8.83 price target.
TDOC presents a turnaround opportunity with attractive valuation metrics (P/S 0.43, EV/EBITDA 6.28) and positive cash flow from operations, but faces significant execution risks from persistent losses, BetterHelp segment challenges, and legal scrutiny. The stock trades near multi-year lows, offering potential upside if management can stabilize the business and return to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →